Arco Lab to Pivot Path demerger scheme becomes effective from June 1
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.4 pts less than Nifty Microcap 250 and 1.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Strides Pharma Science informed that the Scheme of Demerger of the Identified Business of Arco Lab Private Limited into Pivot Path Private Limited has become effective from June 1, 2026. The NCLT Bengaluru Bench had approved the scheme, and the certified copy of the order was received on May 25, 2026. The filing was made by Strides as the listed parent or group entity.
Group-level restructuring between Arco Lab and Pivot Path is now complete. No direct financial impact on Strides shareholders is specified in this intimation.